Core Cap Advisors, LLC Gilead Sciences, Inc. Transaction History

Core Cap Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Aug 08, 2024	BUY	$71.58 - $87.29 $134,570 - $164,105	1,880 New	1,880 $137,000
Q3 2023 Jan 12, 2024	SELL	$73.94 - $80.67 $507,302 - $553,476	-6,861 Closed	0 $0
Q2 2023 Jan 12, 2024	BUY	$76.01 - $86.7 $356,942 - $407,143	4,696 Added 216.91%	6,861 $528,000
Q4 2022 Feb 10, 2023	SELL	$62.32 - $89.47 $1.45 Million - $2.09 Million	-23,311 Reduced 91.5%	2,165 $185,000
Q3 2022 Feb 10, 2023	BUY	$59.54 - $68.01 $1.44 Million - $1.64 Million	24,144 Added 1812.61%	25,476 $1.57 Million
Q2 2022 Aug 11, 2022	BUY	$57.72 - $65.01 $76,883 - $86,593	1,332 New	1,332 $82,000
Q1 2022 Apr 29, 2022	SELL	$57.92 - $72.58 $51,664 - $64,741	-892 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$64.88 - $73.64 $57,872 - $65,686	892 New	892 $65,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Core Cap Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Core Cap Advisors, LLC with notifications on news.